

BEIT JALA PHARMACEUTICAL COMPANY

Financial Statements December 31, 2022

Beit Jala Pharmaceutical Company

Public Shareholding

Statement of Financial Position

As at

	JD	JD
	31/12/2022	31/12/2021
	Audited	Audited
Cash and cash equivalents	1,087,778	851,244
Accounts Receivable	5,385,461	5,067,777
Inventory	3,000,176	3,158,298
Tax advances	327,893	531,515
Prepaid expenses and other debit balances	88,295	133,188
Total Current Assets	9,889,603	9,742,022
Property, plant and equipment	8,757,986	9,305,218
Projects in progress	451,566	598,787
Total Fixed Assets	9,209,552	9,904,005
Total assets	19,099,155	19,646,027
Over Draft	751,129	1,525,646
Short term loans	406,627	647,181
Accounts Payable	1,189,927	1,187,178
Accrued expenses, Provisions, and Credit balances	1,155,220	1,197,038
Income Tax Provision	556,770	477,173
Total Current Liabilities	4,059,673	5,034,216
Long term loans	674,025	1,151,345
Deferred revenues after amortization	13,793	25,754
Provision for employees' indemnity	1,155,837	986,934
Total non-current liabilities	1,843,655	2,164,033
Total Liabilities	5,903,328	7,198,249
Paid-in Capital	7,000,000	7,000,000
Statutory reserve	1,700,106	1,501,998
voluntary reserve	2,587,737	2,191,521
Retained earnings	1,607,326	920,565
Foreign currency translation differences	300,658	833,694
Total Owners' Equity	13,195,827	12,447,778
Total Liabilities & Own	19,099,155	19,646,027

Beit Jala Pharmaceutical Company
Public Shareholding
Income Statement
for the period ending

	JD	JD
	31\12\2022	31\12\2021
	Audited	Audited
Sales	10,767,060	9,755,243
Cost of sales	(6,688,656)	(6,952,382)
Selling and Distribution Expenses	(1,140,834)	(1,094,031)
General and administrative expenses	(583,004)	(601,937)
Financing Income (Losses)	(121,841)	(94,169)
Other revenues (expenses)	11,960	9,314
Foreign currencies exchange gains/Losses	119,902	30,159
Net Income before tax	2,364,587	1,052,197
Income tax expense	(383,502)	(181,103)
Net Income after tax	1,981,085	871,094
Basic and diluted earnings (loss) per share	0.283	0.124
Foreign currency translation differences	(533,036)	267,170
Net Comprehensive Income	1,448,049	1,138,264



Beit Jala Pharmaceutical Company

Public Shareholding

Statement of Owners' Equity

	JD	JD	JD	JD	JD	JD
	Paid-in Capital	Statutory Reserve	Voluntary Reserve	Change in Translation Difference	Retained Earnings	Total Owners' Equity
Balance - Beginning of the period 31/12/2021	7,000,000	1,501,998	2,191,521	833,694	920,565	12,447,778
Net profit or (loss) for the period after tax	-	-	-	-	1,981,085	1,981,085
Statutory Reserve	-	198,109	-	-	(198,109)	0
Voluntary Reserve	-	-	396,217	-	(396,217)	0
Foreign currency translation differences	-	-	-	(533,036)	-	(533,036)
Cash Dividends Paid	-	-	-	-	(700,000)	(700,000)
Income Tax Reconciliation (Previous Years)	-	-	-	-	-	0
Balance - End of the period	-	-	-	-	-	0
Balance - End of the period (Unaudited) 31/12/2022	7,000,000	1,700,107	2,587,738	300,658	1,607,325	13,195,827
Balance - Beginning of the period 31/12/2020	7,000,000	1,414,889	2,017,302	566,524	998,546	11,997,261
Net profit or (loss) for the period after tax	-	-	-	-	871,094	871,094
Statutory Reserve	-	87,109	-	-	(87,109)	-
Voluntary Reserve	-	-	174,219	-	(174,219)	-
Foreign currency translation differences	-	-	-	267,170	-	267,170
Cash Dividends Paid	-	-	-	-	(700,000)	(700,000)
Income Tax Reconciliation (Previous Years)	-	-	-	-	12,253	12,253
Balance - End of the period (audited) 31/12/2021	7,000,000	1,501,998	2,191,521	833,694	920,565	12,447,778

Beit Jala Pharmaceutical Company

Public Shareholding

Cash Flow Statement

End of

	JD	JD
	<u>31\12\2022</u>	<u>31\12\2021</u>
	Audited	Audited
Net Income before/after tax	2,364,587	1,052,197
Depreciation and Amortization expense	938,496	1,055,203
Change in end of service allowance payments	295,125	259,821
Foreign currency translation differences	(533,036)	267,170
Prior year adjustment		
Change in Accounts Receivable	(317,684)	(1,132,796)
Change in inventory	158,122	(882,303)
Change in prepaid expenses and other debit balances	44,893	(6,534)
Change in Accounts Payable	2,759	(35,107)
Accrued expenses and other credit balances	(41,818)	737,922
Income Tax Reconciliation (Previous Years)	(100,285)	(132,643)
Employees' indemnity paid	(126,222)	(94,324)
Net Cash Flow from Operating Activities	2,684,937	1,088,606
Purchase of Property, Plant and Equipment	(403,223)	(820,755)
Change in Projects in Progress	147,221	21,415
Net Cash Flow from Investing Activities	(256,002)	(799,340)
Bank Over Draft	(774,517)	1,525,646
Long term loans	(717,874)	(406,164)
Dividends	(700,000)	(700,000)
Net Cash Flow from Financing Activities	(2,192,391)	419,482
Net change in cash and cash equivalents	236,544	708,748
Cash and cash equivalents, beginning of Period	851,244	142,496
Cash and cash equivalents, end of period	1,087,788	851,244